Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - PLUS THERAPEUTICS, INC. | pstv-ex312_8.htm |
| EX-31.1 - EX-31.1 - PLUS THERAPEUTICS, INC. | pstv-ex311_6.htm |
| 10-Q - 10-Q - PLUS THERAPEUTICS, INC. | pstv-10q_20210331.htm |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Plus Therapeutics, Inc. for the quarterly period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof, Marc H. Hedrick, as President & Chief Executive Officer of Plus Therapeutics, Inc., and Andrew Sims, as VP of Finance and Chief Financial Officer of Plus Therapeutics, Inc., each hereby certifies, respectively, that:
|
1. |
The Form 10-Q report of Cytori Therapeutics, Inc. that this certification accompanies fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934. |
|
2. |
The information contained in the Form 10-Q report of Plus Therapeutics, Inc. that this certification accompanies fairly presents, in all material respects, the financial condition and results of operations of Plus Therapeutics, Inc. |
|
|
|
By: |
|
/s/ Marc H. Hedrick |
|
Dated: April 22, 2021 |
|
|
|
Marc H. Hedrick |
|
|
|
|
|
President & Chief Executive Officer |
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Andrew Sims |
|
Dated: April 22, 2021 |
|
|
|
Andrew Sims |
|
|
|
|
|
Chief Financial Officer & VP of Finance |